Verrica's Skin Cancer Treatment VP-315 Shows 51% Tumor Clearance in Early Trial
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide for treating basal cell carcinoma. The trial showed a 51% complete histological clearance of tumors and an 86% overall reduction in tumor size. No dose-limiting toxicities or serious adverse events were reported. The company plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025.
August 14, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals announced positive preliminary results from its Phase 2 trial for VP-315, showing significant tumor clearance and reduction in size for basal cell carcinoma. No serious adverse events were reported.
The positive preliminary results from the Phase 2 trial for VP-315 indicate significant efficacy in treating basal cell carcinoma, which could lead to increased investor confidence and a potential rise in VRCA's stock price. The absence of serious adverse events further supports the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100